TissueGene: Funding, Investors & Team (Oct 2026)
TissueGene is a Maryland-based biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders. Founded in 1999, the company’s core technology employs a form of cell therapy to deliver therapeutic proteins directly to localized areas of damaged tissue. The sustained expression of such proteins initiates rapid repair of injured tissue without the need for invasive surgical procedures. TissueGene is currently developing four product candidates, TG-C, TG-B, TG-D, and TG-N for the regeneration of cartilage, bone, disc, and nerve, respectively. The company's lead product candidate, TG-C, has been developed for treating osteoarthritis of the knee and is currently in Phase II trials in the US and in Phase III trials in Korea.
TissueGene has raised $30.0M across 1 funding round on record, the most recent an undisclosed round of $30.0M announced in May 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
TissueGene Company Profile and Key Stats
Latest funding round on record: May 2023.
TissueGene Funding Rounds
TissueGene Founders and Leadership Team
No contact details are on record for this team yet.
TissueGene Funding Compared to Other Biotechnology Startups
TissueGene's latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like TissueGene in Biotechnology and Rockville
Companies Similar to TissueGene
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
TissueGene Funding FAQs
What does TissueGene do?
TissueGene is a Maryland-based biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders. Founded in 1999, the company’s core technology employs a form of cell therapy to deliver therapeutic proteins directly to localized areas of damaged tissue. The sustained expression of such proteins initiates rapid repair of injured tissue without the need for invasive surgical procedures. TissueGene is currently developing four product candidates, TG-C, TG-B, TG-D, and TG-N for the regeneration of cartilage, bone, disc, and nerve, respectively. The company's lead product candidate, TG-C, has been developed for treating osteoarthritis of the knee and is currently in Phase II trials in the US and in Phase III trials in Korea.
How much funding has TissueGene raised?
TissueGene has raised $30.0M across 1 round on record. The most recent is an undisclosed round of $30.0M announced in May 2023.
When did TissueGene last raise funding?
TissueGene's most recent funding round on record is an undisclosed round of $30.0M, announced in May 2023.
Who is the CEO of TissueGene?
Moon Jong Noh is listed as CEO at TissueGene.
Where is TissueGene headquartered?
TissueGene is based in Rockville, Maryland, United States.
How many employees does TissueGene have?
TissueGene is in the 1-10 employee band.
How does TissueGene's funding compare to other Biotechnology startups?
TissueGene's latest round of $30.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's TissueGene Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TissueGene is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.